Similar Posts
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeysProfessor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
ByInnokeysApplication for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…
New Marketing Authorization Approval in The Philippines for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeysOn 18 Sep 2020, Philippines FDA approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for nimotuzumab. This…
New Marketing Authorization Approval in Cambodia for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeysOn 24 Sep 2019, Cambodia Ministry of Health approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for…
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
ByInnokeysTokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
Webinar – Current Treatment of Locally Advanced Head and Neck Cancer and The Result of Randomized Phase III Study of Nimotuzumab in Locally Advanced Head and Neck Cancer
ByInnokeysSpeakers: 1. Prof. Iyer Narayanan Gopalakrishna, Head and neck surgeon in National Cancer Centre and Singapore General Hospital 2. Prof. Dr. Kumar…